Abstract
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. It is associated with increased mortality rates as compared to the healthy population. The actual cause of rheumatoid arthritis is unknown although several factors accelerating its progression are outlined. This review enlists various histopathological changes and encompasses a note on its applicability in target specific delivery with the aid of antibodies. There are various first-line, second-line and newer biological treatments available. This review gives brief detail of the novel approaches for the delivery of the targeted as well as non targeted systems like oral, topical, nasal and parenteral and the recent advancements that have been achieved. Moreover, it also gives an account of the amendment that can be made for future with the use of biotechnology, the application of gene profiling and gene array techniques.
Keywords: Antibodies, cytokines, inflammation, line of therapy, rheumatoid arthritis, targeted drug delivery system